Dear colleagues,

Beginning with November 2015 (October ?), we have been noting a dramatic increase in elevated fT3 values (DxI platform, Beckman Coulter) not corresponding to normal TSH. Luckily, we have a second method within reach (cobas, Roche) and most of the falsely elevated fT3 values can be corrected before being reported. However, this comes at some cost and inconvenience (time, reagents, TAT …).

Beckman Coulter has been informed early. According to a recent letter, they “continue to actively investigate the issue”. We hear that a number of European laboratories complained about this particular issue. I would be interested to hear from any of these how they deal with the issue and how Beckman Coulter is expected to solve the trouble.

You may either reply to the list or to my office account as stated below.

Best regards,

Mike

Priv.-Doz. Dr. med. Michael Steiner

Medical Head

Medizinisches Labor Rostock

Südring 81

D-18059 Rostock

[log in to unmask]

Priv.-Doz. Dr. med. Michael Steiner
Arzt für Laboratoriumsmedizin
Ärztlicher Leiter

email: <[log in to unmask]>

Medizinisches Labor Rostock
Labormedizinisches Versorgungszentrum GbR
Südring 81
D-18059 Rostock

Medizinisches Labor Rostock | Südring 81 | D-18059 Rostock

Diese E-Mail enthält vertrauliche und/oder rechtlich geschützte Informationen. Wenn Sie nicht der richtige Adressat sind oder diese E-Mail irrtümlich erhalten haben, informieren Sie bitte sofort den Absender und vernichten Sie diese Mail. Das unerlaubte Kopieren sowie die unbefugte Weitergabe dieser Mail ist nicht gestattet.

This e-mail may contain confidential and/or privileged information. If you are not the intended recipient (or have received this e-mail in error) please notify the sender immediately and destroy this e-mail. Any unauthorised copying, disclosure or distribution of the material in this e-mail is not allowed.